Aldeyra Therapeutics, Inc. (ALDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALDX Stock Price Chart Interactive Chart >
ALDX Price/Volume Stats
| Current price | $3.10 | 52-week high | $13.18 |
| Prev. close | $2.76 | 52-week low | $2.36 |
| Day low | $2.75 | Volume | 417,000 |
| Day high | $3.11 | Avg. volume | 865,974 |
| 50-day MA | $3.71 | Dividend yield | N/A |
| 200-day MA | $5.85 | Market Cap | 180.73M |
Aldeyra Therapeutics, Inc. (ALDX) Company Bio
Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for diseases caused by inflammation and inborn errors of metabolism in the United States and internationally. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts.
Latest ALDX News From Around the Web
Below are the latest news stories about Aldeyra Therapeutics Inc that investors may wish to consider to help them evaluate ALDX as an investment opportunity.
Palatin Technologies: A Diamond In The RoughPalatin Technologies, Inc. (NYSE American: PTN) is a company which I have been following for a number of years, and like many other small biotech companies, the stock has been on somewhat of a roller coaster. When I first started looking into Palatin, the company had no approved drugs and... |
Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming CatalystsNo summary available. |
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Leerink 2022 Global Healthcare ConferenceLEXINGTON, Mass., February 10, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 2022 Global Healthcare Conference. |
Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber ModelLEXINGTON, Mass., February 01, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced that results from the randomized, double-masked, vehicle-controlled, crossover Phase 2 clinical trial of reproxalap in an allergen chamber model have been published in the peer-reviewed journal Clinical Ophthalmology.1 Reproxalap, an investigational new drug, is a first-in-c |
HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ...Stockholm, V7, based Investment company HealthInvest Partners AB (Current Portfolio) buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Bristol-Myers Squibb Co, AbbVie Inc, sells Supernus Pharmaceuticals Inc, Accuray Inc, Aldeyra Therapeutics Inc, Rigel Pharmaceuticals Inc, Evolus Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HealthInvest Partners AB. |
ALDX Price Returns
| 1-mo | -15.07% |
| 3-mo | -24.02% |
| 6-mo | -56.70% |
| 1-year | -75.24% |
| 3-year | -56.21% |
| 5-year | -34.74% |
| YTD | -22.50% |
| 2021 | -41.69% |
| 2020 | 18.07% |
| 2019 | -30.00% |
| 2018 | 22.06% |
| 2017 | 27.10% |
Loading social stream, please wait...